These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31518182)

  • 1. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
    Sears CR; Peikert T; Possick JD; Naidoo J; Nishino M; Patel SP; Camus P; Gaga M; Garon EB; Gould MK; Limper AH; Montgrain PR; Travis WD; Rivera MP
    Am J Respir Crit Care Med; 2019 Sep; 200(6):e31-e43. PubMed ID: 31518182
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
    Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
    J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
    Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
    Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
    Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
    Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
    Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data.
    Liu Q; Zhang C; Huang Y; Huang R; Huang SM; Larkins E; Stapleford L; Rivera DR; Kluetz PG; Wang S; Zhu H; Weese J; Cromartie E; Teka M; Walters S; Wolf F; Brown TD
    Cancer Res Commun; 2023 Feb; 3(2):258-266. PubMed ID: 36860658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
    Suresh K; Naidoo J; Lin CT; Danoff S
    Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary toxicity of systemic lung cancer therapy.
    Long K; Suresh K
    Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.
    Cadranel J; Canellas A; Matton L; Darrason M; Parrot A; Naccache JM; Lavolé A; Ruppert AM; Fallet V
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31597674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
    Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
    Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
    Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.